Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats (original) (raw)

References

  1. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124–34.
    PubMed Google Scholar
  2. Koyasu S. The role of PI3K in immune cells. Nat Immunol. 2003;4:313–9.
    Article PubMed CAS Google Scholar
  3. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3:317–30.
    Article PubMed CAS Google Scholar
  4. Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem. 2009;16:2839–54.
    Article PubMed CAS Google Scholar
  5. Okkenhug K, Bilancio A, Emery JL, Vanhaesebroeck B. Phosphoinositide 3-kinase in T cell activation and survival. Biochem Soc Trans. 2004;32:332–5.
    Article Google Scholar
  6. Rommel C, Camps M, Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 2007;7:191–201.
    Article PubMed CAS Google Scholar
  7. Fruman DA. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signaling in lymphocytes. Biochem Soc Trans. 2004;32:315–9.
    Article PubMed CAS Google Scholar
  8. Soond DR, Bjørgo E, Moltu K, Dale VQ, Patton DT, Torgersen KM, Galleway F, Twomey B, Clark J, Gaston JS, Taskén K, Bunyard P, Okkenhaug K. PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood. 2010;115:2203–13.
    Article PubMed CAS Google Scholar
  9. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. 2000;2:59–64.
    Article PubMed CAS Google Scholar
  10. Zhang HG, Wang Y, Xie JF, Liang X, Liu D, Yang P, Hsu HC, Ray RB, Mountz JD. Regulation of tumor necrosis factor α-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum. 2001;44:1555–67.
    Article PubMed CAS Google Scholar
  11. Ludikhuize J, de Launay D, Groot D, Smeets TJ, Vinkenoog M, Sanders ME, Tas SW, Tak PP, Reedquist KA. Inhibition of forkhead box class O family member transcription factors in rheumatoid synovial tissue. Arthritis Rheum. 2007;56:2180–91.
    Article PubMed CAS Google Scholar
  12. Miyashita T, Kawakami A, Tamai M, Izumi Y, Mingguo H, Tanaka F, Abiru S, Nakashima K, Iwanaga N, Arateke K, Kamachi M, Arima K, Ida H, Migita K, Origuchi T, Tagashira S, Nishikaku F, Eguchi K. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem Biophys Res Commun. 2003;312:397–404.
    Article PubMed CAS Google Scholar
  13. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther. 2006;8:R33.
    Article PubMed Google Scholar
  14. Wang CR, Shiau AL, Chen SY, Lin LL, Tai MH, Shieh GS, Lin PP, Yo YT, Lee CH, Kuo SM, Liu MF, Jou IM, Yang CY, Shen PC, Lee HL, Wu CL. Amelioration of collagen-induced arthritis in rats by adenovirus-mediated PTEN gene transfer. Arthritis Rheum. 2008;58:1650–6.
    Article PubMed CAS Google Scholar
  15. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95–105.
    Article PubMed CAS Google Scholar
  16. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15:5256–67.
    PubMed CAS Google Scholar
  17. Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G. In vitro and in vivo antitumor activity of the phosphatidylinositol 3-kinase inhibitor wortmannin. Anticancer Res. 1995;15:1135–9.
    PubMed CAS Google Scholar
  18. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 2000;6:880–6.
    PubMed CAS Google Scholar
  19. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005;11:936–43.
    PubMed CAS Google Scholar
  20. Stangenberg L, Ellson C, Cortez-Retamozo V, Ortiz-Lopez A, Yuan H, Blois J, Smith RA, Yaffe MB, Weissleder R, Benoist C, Mathis D, Josephson L, Mahmood U. Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function. Arthritis Rheum. 2009;60:2314–24.
    Article PubMed CAS Google Scholar
  21. Newbould BB. Role of lymph nodes in adjuvant-induced arthritis in rats. Ann Rheum Dis. 1964;23:392–6.
    Article PubMed CAS Google Scholar
  22. Jacobson PB, Morgan SJ, Wilcox DM, Nguyen P, Ratajczak CA, Carlson RP, Harris RR, Nuss M. A new spin on an old model: in vivo evaluation of disease progression by magnetic resonance imaging with respect to standard inflammatory parameters and histopathology in the adjuvant arthritic rat. Arthritis Rheum. 1999;42:2060–73.
    Article PubMed CAS Google Scholar
  23. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirano S, Yamazaki K, Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst. 2006;98:545–56.
    Article PubMed CAS Google Scholar
  24. Kong D, Yamori T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms. Cancer Sci. 2007;98:1638–42.
    Article PubMed CAS Google Scholar
  25. Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008;99:1734–40.
    Article PubMed CAS Google Scholar
  26. Kong D, Yaguchi S, Yamori T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol Pharm Bull. 2009;32:297–300.
    Article PubMed CAS Google Scholar
  27. Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin. 2010;31:1189–97.
    Article PubMed CAS Google Scholar
  28. Toyama S, Tamura N, Haruta K, Karakida T, Mori S, Watanabe T, Yamori T, Takasaki Y. Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Arthritis Res Ther. 2010;12:R92.
    Article PubMed Google Scholar
  29. Sugama T. Ishihara N, Tanaka Y, Takahashi M, Yaguchi S, Watanabe T. Amorphous substance of heterocyclic compounds, solid dispersion and pharmaceutical agent containing same, and method of producing same. WO2009066775. 2009.
  30. Van de Langerijt AG, Volsen SG, Hicks CA, Craig PJ, Billingham ME, Van den Berg WB. Cell migration studies in the adoptive transfer of adjuvant arthritis in the Lewis rat. Immunology. 1994;81:414–9.
    PubMed Google Scholar
  31. Bush KA, Walker JS, Lee CS, Kirkham BW. Cytokine expression and synovial pathology in the initiation and spontaneous resolution phases of adjuvant arthritis: interleukin-17 expression is upregulated in early disease. Clin Exp Immunol. 2001;123:487–95.
    Article PubMed CAS Google Scholar
  32. Wesch D, Marx S, Kabelitz D. Monocyte-dependent death of freshly isolated T lymphocytes: induction by phorbolester and mitogens and differential effects of catalase. J Immunol. 1998;161:1248–56.
    PubMed CAS Google Scholar
  33. Wiesenberg I, Van Der Meide PH, Schellekens H, Alkan SS. Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody. Clin Exp lmmunol. 1989;78:245–9.
    CAS Google Scholar
  34. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002;46:802–5.
    Article PubMed CAS Google Scholar
  35. Bober LA, Rojas-Triana A, Jackson JV, Leach MW, Manfra D, Narula SK, Grace MJ. Regulatory effects of interleukin-4 and interleukin-10 in human neutrophil function ex vivo and on neutrophil influx in a rat model of arthritis. Arthritis Rheum. 2000;43:2660–7.
    Article PubMed CAS Google Scholar
  36. Carter AB, Monick MM, Hunninghake GW. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol. 1999;20:751–8.
    PubMed CAS Google Scholar
  37. Kay JE, Benzie CR, Goodier MR, Wick CJ, Doe SEA. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK506. Immunology. 1989;67:473–7.
    PubMed CAS Google Scholar
  38. Yaguchi S, Izumisawa Y, Sato M, Nakagane T, Koshimizu I, Sakita K, Kato M, Yoshioka K, Sakato M, Kawashima S. In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Biol Pharm Bull. 1997;20:698–700.
    Article PubMed CAS Google Scholar
  39. Matsuno T, Karo M, Sasahara H, Watanabe T, Inaba M, Takahashi M, Yaguchi S, Yoshioka K, Sakato M, Kawashima S. Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives. Chem Pharm Bull (Tokyo).2000;48:1778-81.
    Google Scholar
  40. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, Riendeau D, Mancini JA. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol. 2003;170:4738–44.
    PubMed CAS Google Scholar
  41. Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, Gregory SA, Isakson PC. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med. 1996;184:883–91.
    Article PubMed CAS Google Scholar
  42. Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM. Kenneth Haines G III, Kunkel SL, Burdick MD, Koch AE. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. 2000;43:1266–77.
    Article PubMed CAS Google Scholar
  43. Jou S-T, Carpino N, Takahashi Y, Piekorz R, Chao J-R, Carpino N, Wang D, Ihle JN. Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex. Mol Cell Biol. 2002;22:8580–91.
    Article PubMed CAS Google Scholar
  44. Yanaba K, Hamaguchi Y, Venturi GM, Douglas A, Steeber DA, St. Clair EW, Thomas F, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol. 2007;179:1369–80.
    PubMed CAS Google Scholar
  45. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther. 2003;5(Suppl 4):S1–6.
    Article PubMed Google Scholar
  46. Keystone EC. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology. 2005;44:ii8–12.
    Article PubMed CAS Google Scholar

Download references